Search Results - "Davide Ciardiello"

Clinical management of metastatic colorectal cancer in the era of precision medicine by Ciardiello, Fortunato, Ciardiello, Davide, Martini, Giulia, Napolitano, Stefania, Tabernero, Josep, Cervantes, Andres

“…Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as…”
Get full text

Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy by Ciardiello, Davide, Vitiello, Pietro Paolo, Cardone, Claudia, Martini, Giulia, Troiani, Teresa, Martinelli, Erika, Ciardiello, Fortunato

“…•Colorectal cancer is a heterogeneous tumour with different genetic alterations.•Different patterns of immune competence are described in colorectal…”
Get full text

Editorial: Optimizing the first-line treatment for metastatic colorectal cancer by Ciardiello, Davide, Petrillo, Angelica

Get full text

Implication of the Hedgehog pathway in hepatocellular carcinoma by Della Corte, Carminia Maria, Viscardi, Giuseppe, Papaccio, Federica, Esposito, Giovanna, Martini, Giulia, Ciardiello, Davide, Martinelli, Erika, Ciardiello, Fortunato, Morgillo, Floriana

“…The prognosis for patients who are diagnosed with advanced stage hepatocellular carcinoma(HCC)is poor because there are few treatment options.Recent research…”
Get full text

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets by Martini, Giulia, Troiani, Teresa, Cardone, Claudia, Vitiello, Pietropaolo, Sforza, Vincenzo, Ciardiello, Davide, Napolitano, Stefania, Della Corte, Carminia Maria, Morgillo, Floriana, Raucci, Antonio, Cuomo, Antonio, Selvaggi, Francesco, Ciardiello, Fortunato, Martinelli, Erika

“…In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for…”
Get full text

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy by Maiorano, Brigida Anna, Lorusso, Domenica, Maiorano, Mauro Francesco Pio, Ciardiello, Davide, Parrella, Paola, Petracca, Antonio, Cormio, Gennaro, Maiello, Evaristo

“…Ovarian cancer (OC) has a high impact on morbidity and mortality in the female population. Survival is modest after platinum progression. Therefore, the search…”
Get full text

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer by Martini, Giulia, Cardone, Claudia, Vitiello, Pietro Paolo, Belli, Valentina, Napolitano, Stefania, Troiani, Teresa, Ciardiello, Davide, Della Corte, Carminia Maria, Morgillo, Floriana, Matrone, Nunzia, Sforza, Vincenzo, Papaccio, Gianpaolo, Desiderio, Vincenzo, Paul, Mariel C, Moreno-Viedma, Veronica, Normanno, Nicola, Rachiglio, Anna Maria, Tirino, Virginia, Maiello, Evaristo, Latiano, Tiziana Pia, Rizzi, Daniele, Signoriello, Giuseppe, Sibilia, Maria, Ciardiello, Fortunato, Martinelli, Erika

“…The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated EPHA2 as a potential resistance marker to…”
Get full text

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer by Martini, Giulia, Dienstmann, Rodrigo, Ros, Javier, Baraibar, Iosune, Cuadra-Urteaga, Jose Luis, Salva, Francesc, Ciardiello, Davide, Mulet, Nuria, Argiles, Guillem, Tabernero, Josep, Elez, Elena

“…Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several…”
Get full text

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines by Vitiello, Pietro Paolo, Cardone, Claudia, Martini, Giulia, Ciardiello, Davide, Belli, Valentina, Matrone, Nunzia, Barra, Giusi, Napolitano, Stefania, Della Corte, Carmina, Turano, Mimmo, Furia, Maria, Troiani, Teresa, Morgillo, Floriana, De Vita, Ferdinando, Ciardiello, Fortunato, Martinelli, Erika

“…Previous studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to prevent the onset of resistance to…”
Get full text

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives by Ciardiello, Davide, Maiorano, Brigida Anna, Parente, Paola, Rodriquenz, Maria Grazia, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Pazienza, Valerio, Guerrera, Luigi Pio, Amoruso, Brunella, Normanno, Nicola, Martini, Giulia, Ciardiello, Fortunato, Martinelli, Erika, Maiello, Evaristo

“…Biliary tract cancers (BTC) represent a heterogeneous and aggressive group of tumors with dismal prognosis. For a long time, BTC has been considered an orphan…”
Get full text

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC by De Rosa, Caterina, De Rosa, Viviana, Tuccillo, Concetta, Tirino, Virginia, Amato, Luisa, Papaccio, Federica, Ciardiello, Davide, Napolitano, Stefania, Martini, Giulia, Ciardiello, Fortunato, Morgillo, Floriana, Iommelli, Francesca, Della Corte, Carminia Maria

“…Osimertinib is a third-generation tyrosine kinase inhibitor clinically approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC)…”
Get full text

Left abdominal mass with carcinosis: Unusual presentation of pancreatic acinar cell carcinoma by Ciardiello, Davide, Urbano, Filomena, Zamboni, Giuseppe, Palladino, Nicola, Bazzocchi, Francesca, Parente, Paola

Get full text

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer by Maiorano, Brigida Anna, Parisi, Alessandro, Maiello, Evaristo, Ciardiello, Davide

“…Angiogenesis, a hallmark of cancer, plays a fundamental role in colorectal cancer (CRC). Anti-angiogenic drugs and chemotherapy represent a standard of care…”
Get full text

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients by Napolitano, Stefania, Martini, Giulia, Ciardiello, Davide, Di Maio, Massimo, Normanno, Nicola, Avallone, Antonio, Martinelli, Erika, Maiello, Evaristo, Troiani, Teresa, Ciardiello, Fortunato

“…IntroductionImmunotherapy has limited efficacy in metastatic colorectal cancer (mCRC). Understanding mechanisms mediating immune resistance in microsatellite…”
Get full text

Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma by De Falco, Vincenzo, Napolitano, Stefania, Esposito, Daniela, Guerrera, Luigi Pio, Ciardiello, Davide, Formisano, Luigi, Troiani, Teresa

“…Cutaneous melanoma is considered a rare tumor, although it is one of the most common cancers in young adults and its incidence has risen in the last decades…”
Get full text

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer by Ros, Javier, Baraibar, Iosune, Sardo, Emilia, Mulet, Nuria, Salvà, Francesc, Argilés, Guillem, Martini, Giulia, Ciardiello, Davide, Cuadra, José Luis, Tabernero, Josep, Élez, Elena

“…Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and…”
Get full text

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations by Giunta, Emilio Francesco, De Falco, Vincenzo, Napolitano, Stefania, Argenziano, Giuseppe, Brancaccio, Gabriella, Moscarella, Elvira, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa

“…BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as…”
Get full text

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial by Martini, Giulia, Ciardiello, Davide, Napolitano, Stefania, Martinelli, Erika, Troiani, Teresa, Latiano, Tiziana Pia, Avallone, Antonio, Normanno, Nicola, Di Maio, Massimo, Maiello, Evaristo, Ciardiello, Fortunato

“…Monoclonal antibodies targeting EGFR such as cetuximab or panitumumab represent a major step forward in the treatment of wild type (WT) metastatic colorectal…”
Get full text

Beyond N staging in colorectal cancer: Current approaches and future perspectives by Arrichiello, Gianluca, Pirozzi, Mario, Facchini, Bianca Arianna, Facchini, Sergio, Paragliola, Fernando, Nacca, Valeria, Nicastro, Antonella, Canciello, Maria Anna, Orlando, Adele, Caterino, Marianna, Ciardiello, Davide, Della Corte, Carminia Maria, Fasano, Morena, Napolitano, Stefania, Troiani, Teresa, Ciardiello, Fortunato, Martini, Giulia, Martinelli, Erika

“…Traditionally, lymph node metastases (LNM) evaluation is essential to the staging of colon cancer patients according to the TNM (tumor-node-metastasis) system…”
Get full text

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Caputo, Vincenza, De Falco, Vincenzo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Martini, Giulia, Corte, Carminia Maria Della, Ciardiello, Davide, Poliero, Luca, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Franco, Renato, Caraglia, Michele, Avitabile, Arianna, Scalamogna, Roberto, Marchi, Beatrice, Ciardiello, Fortunato, Troiani, Teresa, Napolitano, Stefania

“…Background: Recently, new evidence of the next-generation sequencing (NGS) liquid biopsy utility in clinical practice has been developed. This assay is…”
Get full text